Prelude Therapeutics Incorporated (NASDAQ: PRLD) is a Healthcare company (Biotechnology) with a market capitalization of $192M. The Maz Rating grades it against the other companies in its sector.
Prelude Therapeutics Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $3.32, Prelude Therapeutics Incorporated trades at 8.9x sales and 2.7x book value. Over the last twelve months it generated about $22M of revenue and a net loss of $38M. It runs a gross margin of 72.0%, an operating margin of -283.9% and a net margin of -247.1%. It shows return on equity of -55.1%, return on invested capital of -42.4% and a free cash flow yield of -14.5%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 4.20. Over the past 52 weeks the share price ranged from $1.29 to $6.83, with a beta of 0.96.
Prelude Therapeutics Incorporated does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 5 Buy, 1 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Prelude Therapeutics Incorporated (PRLD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 44.5% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 44.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 44.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.44% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 76.1% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 79.8% / 33.33% · (Cash+Recv) / Total Assets 79.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Prelude Therapeutics Incorporated (PRLD) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Prelude Therapeutics Incorporated is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Prelude Therapeutics Incorporated reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.